RESUMEN
To determine the efficacy of zoledronic acid (ZA) in thalassemia major associated low bone mineral density. Prospective, open label, single arm trial. Bone mineral density (BMD) at lumbar, hip and forearm region were performed at baseline and after 1 year of therapy. Initial, 9 patients received a first dose of 4 mg. Due to severe adverse effects, further doses for these patients and all new recruited patients were 1 mg once every 3 months for 4 doses. All patients were receiving 500 mg of calcium carbonate twice daily and 0.25 µg alfacalcidol once daily before and during the entire study period. Dual energy X-ray absoptiometry was performed at baseline and after 1 year. Twenty-seven patients with transfusion dependent thalassemia with a median age 19.5 year (15-38 years) were eligible for ZA treatment. Seven patients had bony pains. Four patients developed grade 4 hypocalcemia (3 developed tetany) and 2 developed infusion related toxicity with initial dose of 4 mg. One mg dose was well tolerated. At the end of 1 year, bone pains had completely resolved. There was significant increase in BMD at lumbar (p = 0.002) and forearm regions (p = 0.04) and intertrochantric area (p = 0.041). The % change in BMD at 1 year was +3.7 ± 3.2%. ZA is an efficacious agent in treatment of low BMD in these patients. ZA produces significant adverse reactions at 4 mg dose but 1 mg dose is well tolerated and is efficacious.
Asunto(s)
Calidad de Vida , Talasemia beta , Transfusión Sanguínea , Niño , Humanos , Encuestas y CuestionariosAsunto(s)
Enfermedades Hematológicas/diagnóstico , Neoplasias Hematológicas/diagnóstico , Niño , Citometría de Flujo , Enfermedades Hematológicas/clasificación , Enfermedades Hematológicas/terapia , Neoplasias Hematológicas/clasificación , Neoplasias Hematológicas/terapia , Humanos , Inmunofenotipificación , Leucemia/clasificación , Leucemia/diagnóstico , Leucemia/terapia , Linfoma/clasificación , Linfoma/diagnóstico , Linfoma/terapia , Síndromes Mielodisplásicos/clasificación , Síndromes Mielodisplásicos/diagnóstico , Síndromes Mielodisplásicos/terapiaRESUMEN
Myelodysplastic syndrome (MDS) comprises of a heterogeneous group of bone marrow disorders resulting from a clonal stem cell defect characterised by cytopenias despite a relatively hypercellular marrow, ineffective hematopoiesis, morphological dysplasia in the marrow elements, no response to hematinics such as iron, B12 or folic acid and risk of progression to leukemia. Myelodysplastic syndrome in childhood is extremely rare and accounts for less than 5% of all hematopoietic neoplasms in children below the age of 14 y. The primary MDS in children, also known as de novo MDS differs from secondary MDS which generally follows congenital or acquired bone marrow (BM) failure syndromes as well as from therapy related MDS, commonly resulting from cytotoxic therapy. MDS associated with Down syndrome which accounts for approximately one-fourth of cases of childhood MDS is now considered a unique biologic entity synonymous with Down syndrome-related myeloid leukemia and is biologically distinct from other cases of childhood MDS. Refractory cytopenia of childhood (RCC) is the commonest type of MDS. Genetic changes predisposing to MDS in childhood remain largely obscure. Monosomy 7 is by-far the commonest cytogenetic abnormality associated with childhood MDS; however most cases of RCC show a normal karyotype. Complex cytogenetic abnormalities and trisomy 8 and trisomy 21 are also occasionally observed. The most effective and curative treatment is Hematopoietic stem cell transplantation and this is particularly effective in children with the monosomy 7 genetic defect as well as those displaying complex karyotype abnormalities provided it is instituted early in the course of the disease.
Asunto(s)
Síndromes Mielodisplásicos/diagnóstico , Adolescente , Médula Ósea/patología , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/patología , Niño , Preescolar , Deleción Cromosómica , Trastornos de los Cromosomas/diagnóstico , Trastornos de los Cromosomas/genética , Trastornos de los Cromosomas/patología , Cromosomas Humanos Par 7/genética , Cromosomas Humanos Par 8/genética , Diagnóstico Diferencial , Progresión de la Enfermedad , Síndrome de Down/diagnóstico , Síndrome de Down/genética , Síndrome de Down/patología , Hematopoyesis/fisiología , Trasplante de Células Madre Hematopoyéticas , Humanos , Lactante , Cariotipificación , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/patología , Síndromes Mielodisplásicos/genética , Síndromes Mielodisplásicos/patología , Síndromes Mielodisplásicos/terapia , Pronóstico , Factores de Riesgo , Trisomía/diagnóstico , Trisomía/genética , Trisomía/patologíaRESUMEN
Iron deficiency is the most common micronutrient deficiency in the world. Children, particularly infants living in developing countries are highly vulnerable to infectious diseases. Therefore, understanding the relationship between iron deficiency and infection is of great importance. Iron deficiency is associated with impairment of innate (natural) immunity and cell mediated immunity, thereby contributing to increased risk of infections. The iron acquisition by the microbes and their virulence is determined by various host and microbial mechanisms. Altering these mechanisms might provide modes of future therapy for infectious diseases.
Asunto(s)
Anemia Ferropénica/inmunología , Inmunidad , Infecciones/inmunología , Anemia Ferropénica/complicaciones , Control de Enfermedades Transmisibles , Suplementos Dietéticos , Humanos , Huésped Inmunocomprometido , Infecciones/etiología , Hierro/uso terapéuticoAsunto(s)
Anemia Ferropénica/inmunología , Anemia Ferropénica/prevención & control , Promoción de la Salud , Inmunidad Innata , Adolescente , Adulto , Anemia Ferropénica/epidemiología , Anemia Megaloblástica/epidemiología , Anemia Megaloblástica/prevención & control , Preescolar , Femenino , Humanos , India/epidemiología , Lactante , Recién Nacido , Programas Nacionales de Salud , Embarazo , PrevalenciaAsunto(s)
Activación Plaquetaria/inmunología , Púrpura Trombocitopénica/inmunología , Trombopoyesis/inmunología , Autoanticuerpos/metabolismo , Femenino , Humanos , Inmunosupresores/uso terapéutico , Masculino , Activación Plaquetaria/fisiología , Recuento de Plaquetas , Pronóstico , Púrpura Trombocitopénica/diagnóstico , Púrpura Trombocitopénica/tratamiento farmacológico , Medición de Riesgo , Índice de Severidad de la Enfermedad , Trombopoyesis/fisiologíaRESUMEN
BACKGROUND: Glanzmann thrombasthenia (GT) is an autosomal recessive inherited platelet function defect that is characterized by reduction in, or absence of, platelet aggregation in response to multiple physiologic agonists. The defect is caused by mutations in the genes encoding ITGA2B or ITGB3. This results in qualitative or quantitative abnormalities of the platelet receptor, alpha IIb-beta 3. OBJECTIVES: The aim of this study was to identify the mutations in GT patients and to correlate these with patient phenotype. SUBJECTS AND METHODS: A total of 45 unrelated patients with GT were enrolled in the present study to identify the causative molecular defects, and also to correlate their phenotype with their genotype. Platelet aggregation, flow cytometry, Western blotting, and mutation screening by conformation sensitive gel electrophoresis (CSGE) followed by sequencing were performed in all patients. Novel mutations were analyzed for penetrance in individual families. RESULTS: A total of 22 novel mutations were identified in 45 unrelated GT patients. Mutations were identified in 36 of the 45 (80%) patients. Missense mutations were seen in most of the GT patients (59%). The remaining mutations were heterogeneous and were distributed throughout the length of the gene. Analysis of family members showed heterozygous mutations in all families. CONCLUSIONS: The severe type I GT was the most common subtype found in this study. Missense mutations were identified as the defects responsible for most GT patients. Carrier detection and genetic counseling in these families is a potentially effective alternative for decreasing the burden of severe type of GT.
Asunto(s)
Integrina alfa2/genética , Integrina beta3/genética , Mutación , Trombastenia/genética , Adolescente , Adulto , Niño , Preescolar , Análisis Mutacional de ADN , Salud de la Familia , Femenino , Genotipo , Humanos , Lactante , Masculino , Persona de Mediana Edad , Penetrancia , Fenotipo , Agregación Plaquetaria/genética , Adulto JovenAsunto(s)
Leucemia de Células Pilosas/complicaciones , Trombastenia/complicaciones , Examen de la Médula Ósea , Epistaxis/etiología , Enfermedades de las Encías/etiología , Hemorragia/etiología , Humanos , Leucemia de Células Pilosas/diagnóstico , Leucemia de Células Pilosas/metabolismo , Masculino , Microscopía Electrónica , Persona de Mediana Edad , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/metabolismo , Trombastenia/diagnóstico , Trombastenia/metabolismoRESUMEN
BACKGROUND: Hairy-cell leukemia (HCL), lymphoproliferative disease of older age, is characterized by projections from surface of abnormal cells. AIM: The aim was to study the clinical presentation and ultrastructural changes in hairy cells (HCs) following cladribine treatment. SETTINGS AND DESIGN: Clinical presentation, peripheral smear, bone marrow aspiration and biopsy of HCL cases diagnosed over a period of three years were reviewed. MATERIALS AND METHODS: Consecutive HCL cases in Hematology clinic of a tertiary care center were enrolled. Tartarate-resistant acid phosphatase (TRAP) test was done to detect HCs and electron microscopy was done to demonstrate initial ultrastructural changes and alterations following cladribine therapy. RESULTS: Fifteen cases of HCL, aged 32-57 years (median 47 years) were studied. The clinical presentation included splenomegaly in 15 (100%), fever in 10 (67%), hepatomegaly and pain abdomen in eight (53%), fatigue in nine (60 %) cases. The commonest laboratory features were monocytopenia in 13 (87%), neutropenia in 12 (80%), anemia in 10 (67 %) and pancytopenia in nine (60%). All patients showed symptomatic improvement on cladribine therapy. Electron microscopy after treatment (three months) showed loss of the finger like projections, characteristic bald lymphocytes, loss of ribosomal lamellar complexes, as well as decrease in mitochondria and vacuoles. CONCLUSIONS: Indian patients with HCL are younger. Cladribine is an effective therapy for these patients and leads to complete response in most of the patients. There is a significant improvement in the ultrastructural features following cladribine therapy.
Asunto(s)
Antineoplásicos/uso terapéutico , Cladribina/uso terapéutico , Leucemia de Células Pilosas/tratamiento farmacológico , Fosfatasa Ácida/análisis , Adulto , Femenino , Humanos , India , Isoenzimas/análisis , Leucemia de Células Pilosas/patología , Masculino , Microscopía Electrónica , Persona de Mediana Edad , Mitocondrias/ultraestructura , Fosfatasa Ácida TartratorresistenteRESUMEN
Recurrent fetal loss is a frequent health problem. Data accumulated over the past few years have suggested a possible correlation between thrombophilia and fetal loss. Although a clear association has been established between fetal loss and certain thrombophilic states, such as antiphospholipid antibody syndromes, antithrombin deficiency, and combined defects, reports on the prevalence of inherited prothrombotic defects such as factor V Leiden mutation and methylene tetrahydrofolate reductase C677T polymorphism in fetal loss are contradictory. The prevalence of these 2 mutations in Asian Indians with recurrent fetal loss has not yet been studied. In light of this, the present study looked at the prevalence of these mutations in 85 patients with spontaneous recurrent abortion and 31 controls. The authors did not find any significant role of these mutations in the development of recurrent abortion.
Asunto(s)
Aborto Habitual/genética , Factor V/genética , Metilenotetrahidrofolato Reductasa (NADPH2)/genética , Polimorfismo Genético , Aborto Habitual/epidemiología , Aborto Habitual/etiología , Adulto , Estudios de Casos y Controles , Factor V/fisiología , Femenino , Humanos , India/epidemiología , Metilenotetrahidrofolato Reductasa (NADPH2)/fisiología , Mutación Puntual , Embarazo , Prevalencia , Trombofilia/genéticaRESUMEN
A large number of complications in thalassemia major are due mainly to iron overload. Deferoxamine in iron-overloaded patients has established that chelation therapy, when given at an adequate dose, reduces iron-related complications. Parenteral administration and the daily nuisance of an infusion pump hinder the optimal compliance. Deferiprone is moderately effective oral iron chelator. Arthralgia and cytopenias constitute the main side effects. Deferasirox is a new orally effective iron chelator which has been shown to be non-inferior to deferoxamine in clinical trials. Further clinical trials especially in Indian children will tell if it stands the test of time.
Asunto(s)
Benzoatos/uso terapéutico , Quelantes del Hierro/uso terapéutico , Sobrecarga de Hierro/tratamiento farmacológico , Triazoles/uso terapéutico , Talasemia beta/tratamiento farmacológico , Benzoatos/economía , Benzoatos/farmacocinética , Ensayos Clínicos como Asunto , Deferasirox , Deferoxamina/economía , Deferoxamina/farmacocinética , Deferoxamina/uso terapéutico , Humanos , Quelantes del Hierro/economía , Quelantes del Hierro/farmacocinética , Triazoles/economía , Triazoles/farmacocinéticaRESUMEN
The clinical and hematological profile and treatment outcome of children with warm autoimmune hemolytic anemia (AIHA) were assessed using retrospective case record analysis. There were 26 (17 idiopathic; 9 secondary) patients with a median age of 11 years. Pallor (100%), fever (39%), and jaundice (59%) were the main presenting complaints. Jaundice was much more common in idiopathic (70%) compared to secondary (44%). Direct antiglobulin test was negative in 3 patients. Oral prednisolone produced remission in 81% patients. Four patients relapsed after a median period of 7 months (2 months to 2 year) after response. All responded to a second course of steroids in median 14 days. One child required cyclosporin A in addition. No correlation was found between response and parameters such as age, sex, jaundice, low pretreatment hemoglobin, reticulocyte count, total leukocyte count, platelet count, subtype of AIHA, and hepatosplenomegaly. Relapse correlated with increased duration between the onset of symptoms and treatment. This study indicates that oral prednisolone is an effective therapy for autoimmune hemolytic anemia. In refractory cases cyclosporine A may be useful.
Asunto(s)
Anemia Hemolítica Autoinmune/tratamiento farmacológico , Anemia Hemolítica Autoinmune/patología , Adolescente , Niño , Preescolar , Femenino , Fiebre , Humanos , Lactante , Ictericia , Masculino , Palidez , Prednisolona/uso terapéutico , Recurrencia , Inducción de Remisión , Estudios RetrospectivosRESUMEN
Between January 2001 and December 2003, 67 patients with acute leukemia were evaluated prospectively for hemostatic abnormality at presentation, of which 43 (64.2%) had acute lymphoblastic leukemia and 24 (35.8%) had acute myelogenous leukemia. At presentation, 27 patients (40.3%) had bleeding manifestations. Thrombocytopenia was present in 57 patients (85%), and 33(49.3%) had some abnormality of global coagulation markers. Disseminated intravascular coagulation was defined by International Society of Thrombosis and Hemostasis criteria. Disseminated intravascular coagulation was more often associated with bleeding manifestations in acute myelogenous leukemia cases than in acute lymphoblastic leukemia cases. Two patients presented disseminated intravascular coagulation on day 7 of chemotherapy, without any bleeding manifestations. Four of 15 evaluated cases who had a bleeding or infection complication after day 7 of induction therapy also had disseminated intravascular coagulation. It is recommended that all patients with leukemia be investigated for disseminated intravascular coagulation at presentation.